FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case

FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.